Compare Global X Lithium & Battery Tech ETF (LIT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Lithium & Battery Tech ETF vs Recursion Pharmaceuticals Inc — how do they compare? Global X Lithium & Battery Tech ETF trades at $69.73 (market cap $1.45B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap, and Global X Lithium & Battery Tech ETF is more actively traded (89,392 versus 30,789,535). Which is the better fit depends on your goals — on Pluang, investors hold Global X Lithium & Battery Tech ETF for 56 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| LIT | RXRX | |
|---|---|---|
Market Cap | $1.45B | $2.14B |
Volume | 89,392 | 30,789,535 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $91.62 | $6.79 |
52-Week Low | $53.92 | $2.84 |
Typical Hold Time | 56 Days | 23 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LIT trades at $69.73, up 0.32% with mixed technical signals showing a bullish overall trend but bearish moving averages and oscillators. The ETF's price action remains volatile, trading near key support/resistance levels. Recent news highlights significant short interest reduction and ongoing exposure to the lithium and battery technology sector, which faces both supply chain challenges and long-term growth potential from electric vehicle adoption.
The outlook for LIT is cautiously optimistic, driven by global EV adoption trends and energy storage demand, though tempered by lithium price volatility and competitive pressures. Key risks include commodity price swings and geopolitical factors affecting battery supply chains, while institutional sentiment shows mixed signals with technical indicators suggesting near-term consolidation.
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
